Momenta Pharma Q3 revenues soar
The increase in revenue was due to $44.2m of profit share earned from commercial sales of Enoxaparin sodium injection and the $5m regulatory milestone earned upon FDA marketing
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.